RxDoctor Payments Data

Gregory Janda, MD

Urology · Cedar Rapids, IANPI 1245473453

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (57.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 86.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $5,788 and has fallen 83.7% since, to $944 in 2025.

$12,162in general payments, 2019–2025

Across 61 payments — averaging $199.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$11K
  • Procept Biorobotics Corporation$865
  • 180 Medical, Inc.$178
  • Teleflex LLC$108
  • Palette Life Sciences, Inc.$77
  • AbbVie$60
  • plus $371 from 11 others

What the payments were for

  • Travel & lodging$3,94732%
  • Food & beverage$1,21310%
  • Education$7,00258%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,162 in reported general payments places this provider in the 85th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$359,496
Medicare patients
567
Services billed
15,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron208$115,930
Abiraterone Acetate14$19,088
Estradiol84$6,510
Tamsulosin Hcl598$6,126
Testosterone24$5,213
Potassium Citrate ErPotassium Citrate34$3,555
Trospium Chloride116$2,611
Finasteride370$2,597
Solifenacin Succinate58$1,831
Trimethoprim22$1,738
Oxybutynin Chloride ErOxybutynin Chloride59$1,079
Desmopressin Acetate32$883
Cephalexin94$540
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$458
NitrofurantoinNitrofurantoin Macrocrystal15$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$54$115,930208 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 114 urology providers in Iowa.

Other urology in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →